Department of Clinical Medicine

You are here: » CD38 is a potential treatment target in lymphoma patients...

Research

CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Comment/debate/letter to the editor › Research › peer-review

Standard

CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus. / Hybel, Trine Engelbrecht; Vase, Maja Ølholm; Lauridsen, Kristina Lystlund et al.

In: Leukemia and Lymphoma, Vol. 63, No. 6, 05.2022, p. 1479-1483.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Comment/debate/letter to the editor › Research › peer-review

Harvard

Hybel, TE, Vase, MØ, Lauridsen, KL, Enemark, MB, Møller, MB, Pedersen, C, Pedersen, G, Hamilton-Dutoit, S, Obel, N, Schade Larsen, C, d’Amore, F & Ludvigsen, M 2022, 'CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus', Leukemia and Lymphoma, vol. 63, no. 6, pp. 1479-1483. https://doi.org/10.1080/10428194.2021.2023741

APA

Hybel, T. E., Vase, M. Ø., Lauridsen, K. L., Enemark, M. B., Møller, M. B., Pedersen, C., Pedersen, G., Hamilton-Dutoit, S., Obel, N., Schade Larsen, C., d’Amore, F., & Ludvigsen, M. (2022). CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus. Leukemia and Lymphoma, 63(6), 1479-1483. https://doi.org/10.1080/10428194.2021.2023741

CBE

Hybel TE, Vase MØ, Lauridsen KL, Enemark MB, Møller MB, Pedersen C, Pedersen G, Hamilton-Dutoit S, Obel N, Schade Larsen C, et al. 2022. CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus. Leukemia and Lymphoma. 63(6):1479-1483. https://doi.org/10.1080/10428194.2021.2023741

MLA

Hybel, Trine Engelbrecht et al. "CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus". Leukemia and Lymphoma. 2022, 63(6). 1479-1483. https://doi.org/10.1080/10428194.2021.2023741

Vancouver

Hybel TE, Vase MØ, Lauridsen KL, Enemark MB, Møller MB, Pedersen C et al. CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus. Leukemia and Lymphoma. 2022 May;63(6):1479-1483. doi: 10.1080/10428194.2021.2023741

Author

Hybel, Trine Engelbrecht ; Vase, Maja Ølholm ; Lauridsen, Kristina Lystlund et al. / CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus. In: Leukemia and Lymphoma. 2022 ; Vol. 63, No. 6. pp. 1479-1483.

Bibtex

@article{123d636b985f4cefbbbb0458304608a2,
title = "CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus",
author = "Hybel, {Trine Engelbrecht} and Vase, {Maja {\O}lholm} and Lauridsen, {Kristina Lystlund} and Enemark, {Marie Beck} and M{\o}ller, {Michael Boe} and Court Pedersen and Gitte Pedersen and Stephen Hamilton-Dutoit and Niels Obel and {Schade Larsen}, Carsten and Francesco d{\textquoteright}Amore and Maja Ludvigsen",
note = "Funding Information: This work was made possible through Aarhus University, the Karen Elise Jensen Foundation, the Eva and Henry Fraenkel Foundation, the Einar Willumsen{\textquoteright}s Memorial Foundation, and the Danish Lymphoma Group.",
year = "2022",
month = may,
doi = "10.1080/10428194.2021.2023741",
language = "English",
volume = "63",
pages = "1479--1483",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor & Francis ",
number = "6",

}

RIS

TY - JOUR

T1 - CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus

AU - Hybel, Trine Engelbrecht

AU - Vase, Maja Ølholm

AU - Lauridsen, Kristina Lystlund

AU - Enemark, Marie Beck

AU - Møller, Michael Boe

AU - Pedersen, Court

AU - Pedersen, Gitte

AU - Hamilton-Dutoit, Stephen

AU - Obel, Niels

AU - Schade Larsen, Carsten

AU - d’Amore, Francesco

AU - Ludvigsen, Maja

N1 - Funding Information: This work was made possible through Aarhus University, the Karen Elise Jensen Foundation, the Eva and Henry Fraenkel Foundation, the Einar Willumsen’s Memorial Foundation, and the Danish Lymphoma Group.

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85122825283&partnerID=8YFLogxK

U2 - 10.1080/10428194.2021.2023741

DO - 10.1080/10428194.2021.2023741

M3 - Comment/debate/letter to the editor

C2 - 35019824

AN - SCOPUS:85122825283

VL - 63

SP - 1479

EP - 1483

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -